10x Genomics Inc. (TXG) exhibits 69.1% gross margins and -5.7% return on invested capital within Health Care (Biotechnology: Laboratory Analytical Instruments), balanced against a 24.0x enterprise multiple and 4.8% implied options volatility.
Sustained 69.1% gross profitability converts into -9.5% operating margin and -5.7% ROIC, outpacing sector cost of capital.
ROIC: -5.7% // GM: 69.1%YoY revenue trajectory of +5.2% paired with 1.22% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +5.2% // FCF YLD: 1.22%Altman Z-Score of 25.02 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 25.02 // F-SCORE: 8/9Trading at 24.0x trailing P/E (24.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $70.11 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Laboratory Analytical Instruments require continuous execution to defend -6.8% net margins.
NET MARGIN: -6.8% // D/E: 0.13x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for TXG & activate live FRED threshold breach alerts.